. Author manuscript; available in PMC: 2022 Jul 1.

Published in final edited form as: Clin Lung Cancer. 2021 Jan 25;22(4):268–273. doi: 10.1016/j.cllc.2021.01.012

Table 3.

Comparison of the current study with other prospective trials combining RT and CPI immunotherapy.

Author	Cancer Histology	Systemic Therapy	SBRT Dose	SBRT timing (and lesions treated)	Response Rate	Disease Control	Median PFS
This Study	NSCLC	Mostly Pembrolizumab, +/− Chemotherapy	Moderate	Up-Front (single lesion) and Response Adapted	53%	74%	6.9 months
²⁶Theelen et al.	NSCLC	Pembrolizumab	Moderate	Up-Front (single lesion)	36%	61%	6.6 months
²⁷Formenti et al.	NSCLC	Ipilimumab	Moderate	Up-Front (single lesion)	18%	31%	3.8 months
²⁸Luke et al.	Various	Pembrolizumab	High	Up-Front (multiple lesions)	13%	44%	3.1 months
²⁹Welsh et al.	Various	Ipilimumab	High	Up-Front (single lesion)	10%	26%	2.9 months

Abbreviations: SBRT, stereotactic body radiation therapy; PFS, progression-free survival; NSCLC, non-small cell lung cancer